BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 17543345)

  • 1. Cancer immunotherapy, mathematical modeling and optimal control.
    Castiglione F; Piccoli B
    J Theor Biol; 2007 Aug; 247(4):723-32. PubMed ID: 17543345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal control in a model of dendritic cell transfection cancer immunotherapy.
    Castiglione F; Piccoli B
    Bull Math Biol; 2006 Feb; 68(2):255-74. PubMed ID: 16794930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of the optimal therapeutic protocols in cancer immunotherapy.
    Cappuccio A; Castiglione F; Piccoli B
    Math Biosci; 2007 Sep; 209(1):1-13. PubMed ID: 17416392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational modeling of the immune response to tumor antigens.
    Castiglione F; Toschi F; Bernaschi M; Succi S; Benedetti R; Falini B; Liso A
    J Theor Biol; 2005 Dec; 237(4):390-400. PubMed ID: 16039673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Trends in colorectal cancer vaccination].
    Mocellin S; Campana LG
    Recenti Prog Med; 2005; 96(7-8):338-43. PubMed ID: 16209113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting.
    Gray A; Raff AB; Chiriva-Internati M; Chen SY; Kast WM
    Immunol Rev; 2008 Apr; 222():316-27. PubMed ID: 18364011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer vaccines.
    Chekhun VF
    Exp Oncol; 2008 Jun; 30(2):90. PubMed ID: 18680872
    [No Abstract]   [Full Text] [Related]  

  • 8. Dendritic cells and their role in cancer immunotherapy.
    Jalili A
    Iran J Immunol; 2007 Sep; 4(3):127-44. PubMed ID: 17767012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppressive influences in the immune response to cancer.
    Bronte V; Mocellin S
    J Immunother; 2009 Jan; 32(1):1-11. PubMed ID: 19307988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global sensitivity analysis and model-based reactive scheduling of targeted cancer immunotherapy.
    Kiran KL; Lakshminarayanan S
    Biosystems; 2010 Aug; 101(2):117-26. PubMed ID: 20639123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic cells in cancer immunotherapy.
    Vulink A; Radford KJ; Melief C; Hart DN
    Adv Cancer Res; 2008; 99():363-407. PubMed ID: 18037410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic cancer vaccines: an emerging treatment option.
    King SE
    Clin J Oncol Nurs; 2004 Jun; 8(3):271-8. PubMed ID: 15208821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic cancer vaccines.
    Morris LF; Ribas A
    Surg Oncol Clin N Am; 2007 Oct; 16(4):819-31, ix. PubMed ID: 18022546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of dendritic cells in cancer immunotherapy.
    Nencioni A; Grünebach F; Schmidt SM; Müller MR; Boy D; Patrone F; Ballestrero A; Brossart P
    Crit Rev Oncol Hematol; 2008 Mar; 65(3):191-9. PubMed ID: 18055210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mathematical model of pulsed immunotherapy for superficial bladder cancer.
    Bunimovich-Mendrazitsky S; Byrne H; Stone L
    Bull Math Biol; 2008 Oct; 70(7):2055-76. PubMed ID: 18716846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of interleukin-21 immunotherapeutic strategies.
    Cappuccio A; Elishmereni M; Agur Z
    J Theor Biol; 2007 Sep; 248(2):259-66. PubMed ID: 17574601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal control for selected cancer chemotherapy ODE models: a view on the potential of optimal schedules and choice of objective function.
    Engelhart M; Lebiedz D; Sager S
    Math Biosci; 2011 Jan; 229(1):123-34. PubMed ID: 21129386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cell vaccines in melanoma: from promise to proof?
    Lesterhuis WJ; Aarntzen EH; De Vries IJ; Schuurhuis DH; Figdor CG; Adema GJ; Punt CJ
    Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer immunotherapy.
    Baxevanis CN; Perez SA; Papamichail M
    Crit Rev Clin Lab Sci; 2009; 46(4):167-89. PubMed ID: 19650714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active immunotherapy for cancer patients using tumor lysate pulsed dendritic cell vaccine: a safety study.
    Ovali E; Dikmen T; Sonmez M; Yilmaz M; Unal A; Dalbasti T; Kuzeyli K; Erturk M; Omay SB
    J Exp Clin Cancer Res; 2007 Jun; 26(2):209-14. PubMed ID: 17725100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.